<body><div>Despite a congressional inquiry finding fault with the FDA’s controversial approval of aducanumab (Aduhelm), the FDA continues to approve Alzheimer’s drugs that demonstrate little efficacy and high risk of deadly brain bleeding. According to a new BMJ investigation, financial conflicts of interest may help explain why.“A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the ‘independent’ advisory panelists who recommended approval,” according to the BMJ report.The BMJ article, written by independent journalists Jeanne Lenzer and Shannon Brownlee, reveals that many of the advisory committee members who approved recent Alzheimer’s drugs had financial ties to the drugmakers, while others had financial interests in anti-amyloid products in general.This is, in fact, illegal: According to Lenzer and Brownlee, federal law prohibits the FDA’s advisory committee members from having such ties. The FDA granted a waiver to two advisory committee members, which it is permitted to do, but the rest appear to be in violation of federal law.<figure><img src="https://img.particlenews.com/image.php?type=thumbnail_580x000&amp;url=0xT8eb_0vouYuaM00" alt="https://img.particlenews.com/image.php?url=0xT8eb_0vouYuaM00" width="1000" height="667" ></figure>You've landed on a MIA journalism article that is funded by MIA supporters. To read the full article, sign up as a MIA Supporter. All active donors get full access to all MIA content, and free passes to all Mad in America events.Current MIA supporters can log in below.(If you can't afford to support MIA in this way, email us at [email protected] and we will provide you with access to all donor-supported content.)</div></body>

Mountain View, CA

NewsBreak

BMJ: Financial Conflicts of Interest in FDA Advisory Committee May Explain Alzheimer’s Drug Approvals

Despite a congressional inquiry finding fault with the FDA’s controversial approval of aducanumab (Aduhelm), the FDA continues to approve Alzheimer’s drugs that demonstrate little efficacy and high risk of deadly brain bleeding. According to a new BMJ investigation, financial conflicts of interest may help explain why. “A new...